BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pauling JD, Saketkoo LA, Matucci-Cerinic M, Ingegnoli F, Khanna D. The patient experience of Raynaud's phenomenon in systemic sclerosis. Rheumatology (Oxford) 2019;58:18-26. [PMID: 29538754 DOI: 10.1093/rheumatology/key026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Hughes M, Huang S, Pauling JD, Sabbagh M, Khanna D. The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis. Clin Rheumatol 2022. [PMID: 35583625 DOI: 10.1007/s10067-022-06206-y] [Reference Citation Analysis]
2 Maciejewska M, Sikora M, Maciejewski C, Alda-Malicka R, Czuwara J, Rudnicka L. Raynaud's Phenomenon with Focus on Systemic Sclerosis. J Clin Med 2022;11:2490. [PMID: 35566614 DOI: 10.3390/jcm11092490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lescoat A, Murphy SL, Chen YT, Vann N, Galdo FD, Cella D, Buch MH, Khanna D. Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study✰,✰✰,★,★★. Semin Arthritis Rheum 2021:S0049-0172(21)00199-2. [PMID: 34785028 DOI: 10.1016/j.semarthrit.2021.11.003] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Galetti I, Nunzio SD, Brogelli L, Mirisola V, Garbagnati C. How do systemic sclerosis manifestations influence patients' lives? Results from a survey on patients and caregivers. Curr Med Res Opin 2021;37:5-15. [PMID: 34726112 DOI: 10.1080/03007995.2021.1992371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Herrick AL. Raynaud's phenomenon and digital ulcers: advances in evaluation and management. Curr Opin Rheumatol 2021;33:453-62. [PMID: 34420003 DOI: 10.1097/BOR.0000000000000826] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Saketkoo LA, Frech T, Varjú C, Domsic R, Farrell J, Gordon JK, Mihai C, Sandorfi N, Shapiro L, Poole J, Volkmann ER, Lammi M, McAnally K, Alexanderson H, Pettersson H, Hant F, Kuwana M, Shah AA, Smith V, Hsu V, Kowal-Bielecka O, Assassi S, Cutolo M, Kayser C, Shanmugam VK, Vonk MC, Fligelstone K, Baldwin N, Connolly K, Ronnow A, Toth B, Suave M, Farrington S, Bernstein EJ, Crofford LJ, Czirják L, Jensen K, Hinchclif M, Hudson M, Lammi MR, Mansour J, Morgan ND, Mendoza F, Nikpour M, Pauling J, Riemekasten G, Russell AM, Scholand MB, Seigart E, Rodriguez-Reyna TS, Hummers L, Walker U, Steen V. A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. Best Pract Res Clin Rheumatol 2021;35:101707. [PMID: 34538573 DOI: 10.1016/j.berh.2021.101707] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 van Leeuwen NM, Ciaffi J, Liem SIE, Huizinga TWJ, de Vries-Bouwstra JK. Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. Rheumatology (Oxford) 2021;60:3646-55. [PMID: 33401302 DOI: 10.1093/rheumatology/keaa827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Pauling JD, Christopher-Stine L. The aetiopathogenic significance, clinical relevance and therapeutic implications of vasculopathy in idiopathic inflammatory myopathy. Rheumatology (Oxford) 2021;60:1593-607. [PMID: 33458769 DOI: 10.1093/rheumatology/keaa816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Maltez N, Hughes M, Brown E, Hickey V, Park H, Shea B, Herrick AL, Pauling JD, Proudman S, Merkel PA. Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020. Semin Arthritis Rheum 2021;51:640-3. [PMID: 33947582 DOI: 10.1016/j.semarthrit.2021.04.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Murphy SL, Lescoat A, Alore M, Hughes M, Pauling JD, Sabbagh M, Khanna D. How do patients define Raynaud's phenomenon? Differences between primary and secondary disease. Clin Rheumatol 2021;40:1611-6. [PMID: 33486597 DOI: 10.1007/s10067-021-05598-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Roennow A, Sauvé M, Welling J, Riggs RJ, Kennedy AT, Galetti I, Brown E, Leite C, Gonzalez A, Portales Guiraud AP, Houÿez F, Camp R, Gilbert A, Gahlemann M, Moros L, Luna Flores JL, Schmidt F, Sauter W, Finnern H. Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations. BMJ Open 2020;10:e039473. [PMID: 33328257 DOI: 10.1136/bmjopen-2020-039473] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Pettersson H, Nordin A, Svenungsson E, Alexanderson H, Boström C. Experiences of physical activity and exercise in individuals with systemic sclerosis: A qualitative study. Musculoskeletal Care 2020;18:150-60. [DOI: 10.1002/msc.1447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
13 Khanna D, Allanore Y, Denton CP, Matucci-cerinic M, Pope J, Hinzmann B, Davies S, de Oliveira Pena J, Distler O. Patient perception of disease burden in diffuse cutaneous systemic sclerosis. Journal of Scleroderma and Related Disorders 2020;5:66-76. [DOI: 10.1177/2397198319866615] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
14 Pauling JD, Hughes M, Pope JE. Raynaud's phenomenon-an update on diagnosis, classification and management. Clin Rheumatol 2019;38:3317-30. [PMID: 31420815 DOI: 10.1007/s10067-019-04745-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
15 Pauling JD, Reilly E, Smith T, Frech TM. Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient-Reported Assessments of Disease Severity. Arthritis Care Res (Hoboken) 2019;71:1119-26. [PMID: 30133174 DOI: 10.1002/acr.23729] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
16 Pauling JD, Reilly E, Smith T, Frech TM. Factors Influencing Raynaud Condition Score Diary Outcomes in Systemic Sclerosis. J Rheumatol 2019;46:1326-34. [PMID: 30824643 DOI: 10.3899/jrheum.180818] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
17 Pauling JD, Nagaraja V, Khanna D. Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis. Curr Treat Options in Rheum 2019;5:85-103. [DOI: 10.1007/s40674-019-00118-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
18 Hughes M, Baker A, Farrington S, Pauling JD. Patient organisation-led initiatives can play an important role in raising awareness about Raynaud's phenomenon and encourage earlier healthcare utilisation for high-risk groups. Ann Rheum Dis 2019;78:439-41. [PMID: 30309971 DOI: 10.1136/annrheumdis-2018-214161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
19 Pauling JD. The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis. Expert Rev Clin Immunol 2018;14:431-42. [PMID: 29641934 DOI: 10.1080/1744666X.2018.1464390] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]